NEW YORK (
CHANGE IN RATINGS
upgraded at Oppenheimer from Market Perform to Outperform. $62 price target. Stock is already factoring in pricing risks in Europe.
rated new Hold at Stifel Nicolaus. Valuation call, as sales could be hurt by macro issues and currency headwinds.
downgraded at Barclays to Equal Weight from Overweight on high inventory and a merchant change. Price target dropped to $6 from $10. 2010 and 2011 EPS estimates lowered to $0.03 and $0.20, respectively.
upgraded at JP Morgan. Rating raised to Overweight from Neutral. Price target raised to $77.50 from $71.00. Maintains 2010 EPS estimates of $2.56.
upgraded at MKM from Sell to Neutral. Stock is down 19% since earnings, and lacks further potential negative catalysts.
Don't Miss Top 10 Buy-Rated Stocks Under $5
rated new Hold at Citigroup. $17 price target. Earnings momentum has likely peaked and the stock is already up 143% over the past year.
Las Vegas Sands
upgraded at Morgan Stanley from Equal-weight to Overweight. $29 price target. Estimates also boosted, given ramping business at Marina Bay.
Procter & Gamble
rated new Buy at Stifel Nicolaus. $72 price target. Company should continue to post accelerating sales growth.
upgraded at FBR from Market Perform to Outperform. $33 price target. Company has a healthy business pipeline.
STOCK COMMENTS / EPS CHANGES
estimates lower at Credit Suisse. HOV 2011 and 2012 EPS estimates sunk to -$1.90 and -$0.60, respectively. Maintain Underperform rating and $2 price target.
estimates raised at Oppenheimer through 2012. Market is not yet factoring in the company's cost-savings efforts. Outperform rating and $22 price target.
estimates, target boosted at Jefferies. Shares of HXL now seen reaching $17. Estimates also upped, given the company's opportunities in the aircraft and wind turbine markets. Hold rating.
target, estimates higher at Barclays JBLU price target raised to $10 from $8 on strong revenue recovery and declining fuel. Estimates raised through 2011. Maintain Equal Weight rating.
estimates lowered at UBS. ORCL estimates were reduced through 2011. Company could be hurt by currency headwinds. Buy rating and $31 price target.
This article was written by a staff member of TheStreet.com.